These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30404557)

  • 1. Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.
    Hart NJ; Weber C; Papas KK; Limesand SW; Vagner J; Lynch RM
    Am J Physiol Cell Physiol; 2019 Jan; 316(1):C48-C56. PubMed ID: 30404557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells.
    Hart NJ; Chung WJ; Weber C; Ananthakrishnan K; Anderson M; Patek R; Zhang Z; Limesand SW; Vagner J; Lynch RM
    Chembiochem; 2014 Jan; 15(1):135-45. PubMed ID: 24259278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced GLP-1- and sulfonylurea-induced insulin secretion in islets lacking leptin signaling.
    Morioka T; Dishinger JF; Reid KR; Liew CW; Zhang T; Inaba M; Kennedy RT; Kulkarni RN
    Mol Endocrinol; 2012 Jun; 26(6):967-76. PubMed ID: 22474124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Function and expression of sulfonylurea, adrenergic, and glucagon-like peptide 1 receptors in isolated porcine islets.
    Kelly AC; Steyn LV; Kitzmann JP; Anderson MJ; Mueller KR; Hart NJ; Lynch RM; Papas KK; Limesand SW
    Xenotransplantation; 2014; 21(4):385-91. PubMed ID: 24801676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?
    Whalley NM; Pritchard LE; Smith DM; White A
    J Endocrinol; 2011 Oct; 211(1):99-106. PubMed ID: 21795304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose.
    Zhang Y; Han C; Zhu W; Yang G; Peng X; Mehta S; Zhang J; Chen L; Liu Y
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine.
    Doliba NM; Qin W; Vatamaniuk MZ; Li C; Zelent D; Najafi H; Buettger CW; Collins HW; Carr RD; Magnuson MA; Matschinsky FM
    Am J Physiol Endocrinol Metab; 2004 May; 286(5):E834-43. PubMed ID: 14736703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.
    Flamez D; Van Breusegem A; Scrocchi LA; Quartier E; Pipeleers D; Drucker DJ; Schuit F
    Diabetes; 1998 Apr; 47(4):646-52. PubMed ID: 9568699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from β-cells.
    Wu B; Wei S; Petersen N; Ali Y; Wang X; Bacaj T; Rorsman P; Hong W; Südhof TC; Han W
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9996-10001. PubMed ID: 26216970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets.
    Luo G; Kong X; Lu L; Xu X; Wang H; Ma X
    Int J Biochem Cell Biol; 2013 Feb; 45(2):483-90. PubMed ID: 23220045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study.
    Riz M; Pedersen MG; Toffolo GM; Haschke G; Schneider HC; Klabunde T; Margerie D; Cobelli C
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(6):E627-34. PubMed ID: 24425760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.
    Yang Y; Tong Y; Gong M; Lu Y; Wang C; Zhou M; Yang Q; Mao T; Tong N
    Cell Signal; 2014 Feb; 26(2):268-78. PubMed ID: 24269940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
    Fehmann HC; Habener JF
    FEBS Lett; 1991 Feb; 279(2):335-40. PubMed ID: 1672112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells.
    Ma X; Guan Y; Hua X
    J Diabetes; 2014 Sep; 6(5):394-402. PubMed ID: 24725840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells.
    Fehmann HC; Janssen M; Göke B
    Acta Diabetol; 1995 Oct; 32(3):176-81. PubMed ID: 8590787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function.
    Omar B; Sörhede-Winzell M; Ahrén B
    Metabolism; 2014 Dec; 63(12):1568-76. PubMed ID: 25301258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthreshold α₂-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion.
    Pan M; Yang G; Cui X; Yang SN
    Exp Diabetes Res; 2011; 2011():604989. PubMed ID: 21253359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.